My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$WMB {{ '2015-10-29T11:15:31+0000' | timeago}} • Announcement

Natural gas pipeline powerhouse $WMB reported 3Q15 loss of $40MM or $0.05 per diluted share compared to net income of $1.678Bil or $2.22 in the same period last year. Adjusted income from continuing operations was $167MM or $0.22 per share compared to $157MM or $0.21 per share in third quarter of 2014.

User Vishnu Beri {{ '2016-10-25T21:15:45+0000' | timeago}}

Apple ($AAPL) reported decline in sales and profits from comparable quarter last year, attributing the decline to announcement of iPhone 7/7s. Sales and profit are being guided higher for next quarter. Apple is a solid company and will continue to dominate tech and consumer electronics segment for a while. Personally, looks like there is little downside in this investment.

User Mark Collas {{ '2016-10-25T20:12:01+0000' | timeago}}

Waiting with fingers crossed for $AAPL’s fourth quarter earnings.

User RC xNair {{ '2016-10-25T17:04:47+0000' | timeago}}

Looking ahead to $AAPL earnings release later in the afternoon today? Gene Munster, analyst from Piper Jaffrey and the most respected authority for Apple, had this to say - "The second and slightly larger group of investors believe the tail of the iPhone 7 is irrelevant, and is betting that the iPhone 10th Anniversary will yield a jump in growth from flat to up ~15%."

User Carlton Davis {{ '2016-10-24T19:31:20+0000' | timeago}}

$COL agreed to buy $BEAV for $6.4 billion in cash and stock. Also Rockwell Collins reported higher 4Q16 earnings on growth in Government Systems and higher revenue in Information Management Services.

User Charles Elliston {{ '2016-10-24T19:15:21+0000' | timeago}}

Wow! What a buzz the $T-$TWX deal is making! Almost everyone from politicians to competitors have come out against this deal. Even Wall Street doesn’t seem to be too thrilled. Both stocks were down today.

$NDAQ {{ '2016-10-26T13:34:03+0000' | timeago}} • Webcast

$NDAQ said it received large group of Canadian clients now with the acquisition of Marketwired in the Corporate Solutions business. The company now have the opportunity to cross sell other services since it's a primary market for the clients.

$GRMN {{ '2016-10-26T13:32:14+0000' | timeago}} • Announcement

Technology company $GRMN reported a rise in 3Q16 earnings as four of its five business segments delivered double digit sales growth and increased profitability. Net income rose to $125.05MM or $0.66 per share from $119.3MM or $0.63 per share last year. Net sales grew 6% to $722.25MM. Pro forma EPS increased 47% to $0.75.

$NDAQ {{ '2016-10-26T13:29:43+0000' | timeago}} • Webcast

$NDAQ's data products revenues rose $6MM to $109MM in 3Q16, helped by revenues from the ISE and Nasdaq CXC acquisitions as well as higher audit collections. Listing Services revenues grew $2MM to $68MM, helped by higher revenues in the Nordics due to new company listings.

$MDLZ {{ '2016-10-26T13:25:26+0000' | timeago}} • Announcement

For the full year, $MDLZ expects organic revenue growth of approx. 1.6%.The company raised its full-year Adjusted EPS outlook to a growth of approx. 25%. Based on foreign exchange rates as of Oct. 21, there would be a negative translation impact on FY net revenue growth of approx. 4 percentage points and on FY Adjusted EPS of approximately $0.09.

$BIIB {{ '2016-10-26T13:23:22+0000' | timeago}} • Webcast

$BIIB's collaboration partner Eisai has stated their goal to start a Phase III trial for E2609. A $50MM milestone payment is expected to be triggered once the first patient is dosed in the trial. There is a potential chance they could dose the first patient by the end of 2016. The $50MM milestone was not considered in the mid-year 2016 R&D outlook.